SENSORIUM THERAPEUTICS INC
MEDFORD, MA · Founded 2021 · CIK 0001874823 · Biotech · Private
Novel CNS therapeutics derived from natural compounds
sensorium.bio →- Grants
- $2.0M
- 2 awards
- Sector median: 1
- Raised
- $39M
- 3 Form D · Feb 2025
- 20 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $9,000,000 | |
| Private capital raised | Form D · SEC | $15,512,569 | |
| Federal grant | Department of Health and Human Services · Phase II · A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment | $502,499 | |
| Private capital raised | Form D · SEC | $14,496,526 | |
| Federal grant | Department of Health and Human Services · Phase II · A Drug Discovery Platform to Prioritize Development of Natural Product Neuromodulators for Treating Cognitive Impairment | $1,517,441 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2124 | PERIOMICS CARE LLC | — | — |
| 2125 | Apricity Therapeutics | — | — |
| 2126 | Lygos, Inc. | — | $41M |
| 2127 | SENSORIUM THERAPEUTICS INC | — | $39M |
| 2128 | CMTX BIOTECH INC | — | $500K |
| 2129 | ProMIS Neurosciences Inc. | — | $39M |
| 2130 | CASI Pharmaceuticals, Inc. | — | $35M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Balkrishan GillDirector
- Alexandra GlucksmannDirector · Executive Officer
- Jacob HookerDirector · Executive Officer
- Ryan KatzDirector
- Kevin LalandeDirector
- Jerrold RosenbaumDirector
- Richard SimonDirector · Executive Officer
- David SouthwellDirector
- Pranav TadiExecutive Officer
Patents
- Deuterated Forms Of Alkaloid Compounds And Therapeutic Uses Thereofapplication
- Delivery Of Therapeutic Alkaloid Compoundsapplication
- Therapeutic Alkaloid Compoundsapplication
- Solid Forms Of Mesembrine And Therapeutic Uses Thereofapplication
- Delivery Of Therapeutic Alkaloid Compoundsapplication
- Therapeutic Alkaloid Compoundsapplication
- Therapeutic Alkaloid Compoundsgranted
- Delivery Of Therapeutic Alkaloid Compoundsapplication
- Delivery Of Therapeutic Alkaloid Compoundsgranted
- Solid Forms Of Mesembrine And Therapeutic Uses Thereofapplication
- Therapeutic Alkaloid Compoundsapplication
- Delivery Of Therapeutic Alkaloid Compoundsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.